Botulinum Toxin for Drooling in Adults with Diseases of the Central Nervous System: A Meta-Analysis.
Healthcare (Basel)
; 11(13)2023 Jul 06.
Article
em En
| MEDLINE
| ID: mdl-37444790
ABSTRACT
(1) Background:
The purpose of this study was to determine whether the drooling of adult patients with diverse central nervous system diseases can be treated with botulinum toxin type A. (2)Methods:
The Cochrane Library, MEDLINE, and Embase were all searched for studies that fit the inclusion criteria. The patients in the studies had to be adults (>18 years old), and the studies had to be randomized placebo-controlled trials, controlled trials, or prospective studies. Each study had to have enough quantifiable data available for meta-analysis. The primary outcome measure was the Drooling Severity and Frequency Scale (DSFS). (3)Results:
The meta-analysis comprised three studies. A statistically significant difference in DSFS score between the treatment and control groups was observed in the meta-analysis, with an overall standardized mean difference of -0.9377 (95% CI, -1.2919 to -0.5836; p < 0.0001). A total of seven studies were ineligible for inclusion in the meta-analysis and were only assessed as qualitative data. All qualitative studies showed a significant reduction in DSFS score a few weeks or months after the injection of botulinum toxin. (4)Conclusions:
Botulinum toxin type A is safe and effective as a treatment for drooling in adult patients with central nervous system diseases.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Observational_studies
/
Qualitative_research
/
Systematic_reviews
Idioma:
En
Revista:
Healthcare (Basel)
Ano de publicação:
2023
Tipo de documento:
Article